OR WAIT 15 SECS
Lygos CBx uses fermentation-based technology for the production of cannabinoids for consumer and pharmaceutical applications.
Lygos Inc. (Berkeley, CA) launched Lygos CBx, a company focused on delivering high quality, pure, and sustainable non-plant-based cannabinoids. Lygos CBx uses fermentation-based technology for the production of cannabinoids for consumer and pharmaceutical applications. The new company is the result of combining the recently acquired NIH-funded biosynthetic company Librede with key Lygos technological advances. The novel fermentation process, according to the company, is environmentally safe, sustainable, and cost effective for commercial applications.
The novel process can produce specific, and isolated cannabinoids, avoiding issues of separation and purification associated with plant-based production, and the modular platform allows Lygos CBx to produce both acidic and decarboxylated forms. Lygos CBx offers a full menu of cannabinoids including CBD, CBG, CBC, CBN, CBGA, CBCA, CBDA, and CBDV, as well as services such as bulk supply, formulation, custom synthesis, and efficacy services.
“The launch of Lygos CBx is a reflection of all the hard work required to develop a novel production platform that can introduce disruptive consumer products and brands in a rapid and repeatable manner,” said Eric Steen, PhD, CEO of Lygos, in a press release. “Today, we are currently delivering high-quality, ultra-pure and sustainable cannabinoids and partnering with industry leaders to help meet the growing demand for these next-generation products.”